SNS-595 Study Data To Be Presented This Weekend
By M.S.W. ZoeMed Inc. Copyright © 2004 All rights Reserved
--------------------------------------------------------------------------------

Sunesis Pharmaceuticals has announced that two abstracts addressing studies of SNS-595 have been accepted for presentation at the 95th Annual Meeting of the American Association of Cancer Research (AACR) to be held this weekend in Orlando. SNS-595 is a novel cytotoxic anti-cancer agent under development to address certain solid tumor cancers.

SNS-595 is a cell cycle modulator that arrests the characteristic proliferation of cancer cells by inducing apoptosis or cell death. In vivo studies of SNS-595 have demonstrated exceptional activity as well as marked potency in comparison to marketed cytotoxics such as paclitaxel and irrinotecan. In addition SNS-595 has been shown to be highly active in drug- resistant tumor models.

"SNS-595 has demonstrated broad cytotoxic activity in some challenging tumor models and we are enthusiastic about the opportunity to share the results of these pre-clinical studies in a peer-review setting " said Daniel Adelman M.D. Senior Vice President of Development for Sunesis. "There is a clear need for next-generation cytotoxic therapeutics with the ability to target and destroy tumor cells. SNS-595 has shown promising and robust activity in pre-clinical studies supporting our plans to initiate clinical testing in humans later this year."


Cancer LifeCenter Article 9374